IP Library Granted Patent US 8,383,597
Granted Patent B2
US 8,383,597 · App. 11/805,715 · Granted Feb 26, 2013

G proteins in tumor growth and angiogenesis

Inventor: Xin-Yun Huang (New York, NY)
Assignee: Cornell Research Foundation, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,383,597
App. No.
11/805,715
Granted
Feb 26, 2013
Kind
B2
Abstract

The invention provides an agent that reduces the expression of Gα 12 or Gα 13 polypeptide, as well as an agent that enhances G protein Gα 12 or Gα 13 expression and/or activity. An agent of the invention may be used to decrease or increase G protein Gα 12 or Gα 13 expression and/or activity thereby to treat or prevent the onset of a disease or condition associated with Gα 12 or Gα 13 expression and/or activity. The invention also provides a method for screening for an anti-cancer or anti-angiogenesis agent, as well as an agent that promotes angiogenesis.

Claims (12)

1. A method for inhibiting angiogenesis in a mammal, the method comprising inhibiting the expression and/or activity of Gα 13 in the mammal by administering a guanine diphosphate or guanine triphosphate analogue selected from the group consisting of GDP beta S, GppNHp, and GppCH2p, with a small interfering RNA capable of hybridizing to a nucleic acid encoding a Gα 13 polypeptide under intracellular conditions and reducing expression of the Gα 13 protein in a cell, or any combination thereof in an amount effective to decrease expression and/or activity of the Gα 13 polypeptide.

2. The method of claim 1 , wherein the small interfering RNA has a sequence selected from the group consisting of SEQ ID NO: 6-9 and 69-145.

3. The method of claim 1 , wherein the mammal has cancer.

4. The method of claim 1 , wherein the small interfering RNA, analogue or any combination thereof is administered by direct injection to a localized area.

5. The method of claim 1 , wherein the expression and/or activity of Gα 12 or Gα 13 is decreased by about 20% to about 90%.

6. The method of claim 1 wherein the expression and/or activity of Gα 12 or Gα 13 is decreased by about 30% to about 70%.

7. The method of claim 1 , wherein the method further comprises inhibiting endothelial cell migration.

8. A method for inhibiting angiogenesis in a mammal, the method comprising inhibiting the expression and/or activity of Gα 13 in the mammal by administering a small interfering RNA having a sequence selected from the group consisting of SEQ ID NO: 6-9 and 69-145, or a complement thereof.

9. The method of claim 8 , further comprising administering a small interfering RNA having a sequence selected from the group consisting SEQ ID NO: 11-68.

10. A method for inhibiting angiogenesis in a mammal, the method comprising administering an antibody and a small interfering RNA having a sequence selected from the group consisting of SEQ ID NO: 6-9 and 69-145.

11. The method of claim 10 , wherein the antibody reduces angiogenesis.

12. The method of claim 10 , wherein the antibody binds to the Gα 13 polypeptide.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 25, 2016
From: CORNELL UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039809/0899 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2007
From: HUANG, XIN-YUN
To: CORNELL RESEARCH FOUNDATION, INC.
Reel/Frame 019696/0501 →
Continuity (2)
Provisional Application 60808489 · May 25, 2006
Related Publication 20080020994A1 · Jan 24, 2008